Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Ekso Bionics Holdings Inc. (EKSO:NASDAQ), powered by AI.
Ekso Bionics Holdings Inc. is currently trading at $11.80. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Ekso Bionics Holdings Inc. on Alpha Lenz.
Ekso Bionics Holdings Inc.'s P/E ratio is -2.4.
“Ekso Bionics Holdings Inc. trades at a P/E of -2.4 (undervalued) with modest ROE of -107.6%.”
Ask for details →Ekso Bionics Holdings Inc. is a company that specializes in the development and production of wearable exoskeletons. These innovative robotic devices are primarily designed to augment human strength, endurance, and mobility, offering significant advancements in both medical and industrial sectors. In healthcare, Ekso Bionics focuses on rehabilitation solutions, aiding patients in recovery from spinal cord injuries and other mobility impairments by providing supportive walking assistance. Industrial applications, on the other hand, leverage their exoskeletons to reduce worker fatigue and prevent injuries in physically demanding roles, such as construction or manufacturing. Founded in 2005 and headquartered in Richmond, California, Ekso Bionics is at the forefront of the wearable robotics industry, positioning itself as a pioneer in a niche yet rapidly growing market. The company's technology not only improves quality of life and productivity for individuals but also introduces substantial efficiencies and safety enhancements in various labor-intensive environments. Through its contributions, Ekso Bionics introduces new paradigms in human-machine interfaces and rehabilitation technologies.
“Ekso Bionics Holdings Inc. trades at a P/E of -2.4 (undervalued) with modest ROE of -107.6%.”
Ask for details →Ekso Bionics Holdings Inc. (ticker: EKSO) is a company listed on NASDAQ in the Healthcare sector (Medical Instruments & Supplies). It has approximately 61 employees. Market cap is $29M.
The current price is $11.8 with a P/E ratio of -2.45x and P/B of 3.17x.
ROE is -107.62% and operating margin is -104.12%. Annual revenue is $13M.